Human iPSC-derived iMSCs improve bone regeneration in mini-pigs

Area of Science:

• Regenerative Medicine
• Biomaterials Science
• Orthopedic Research

Background:

• Autologous bone marrow concentrate (BMC) and mesenchymal stem cells (MSCs) aid bone defect healing.
• Primary MSCs have limitations, leading to the development of induced pluripotent stem cell-derived MSCs (iMSCs).

Purpose of the Study:

• To evaluate the bone regeneration capacity of human iMSCs combined with calcium phosphate granules (CPG).
• To compare iMSC+CPG treatment with autografts, BMC+CPG, and CPG alone in critical-size bone defects.

Main Methods:

• Human iMSCs were derived from human fetal foreskin fibroblasts (HFFs).
• iMSCs were characterized for osteogenic differentiation and expression of bone morphogenic proteins (BMPs) and cytokines.
• Critical-size defects in mini-pig tibias were treated with HFF-iMSC+CPG, autologous BMC+CPG, or CPG alone.
• Radiological and histomorphometric analyses were performed at 6 weeks.

Main Results:

• HFF-iMSCs differentiated into osteoblasts in vitro and secreted relevant signaling molecules.
• HFF-iMSC+CPG treatment led to significantly better osseous consolidation than CPG alone.
• Outcomes for HFF-iMSC+CPG were not significantly different from autologous BMC+CPG treatment.

Conclusions:

• iMSCs combined with CPG show significant potential for bone regeneration.
• This approach offers a viable alternative to autografts for treating load-bearing bone defects.
• iMSCs represent a promising future therapeutic option in orthopedics.